两种用药方案治疗食管反流性咽喉炎的疗效比较

Clinical effects of mosapride plus ranitidine vs mosapride plus rabeprazole for treatment of esophageal reflux laryngitis

目的:探讨临床上应用莫沙必利与雷贝拉唑联合治疗食管反流性咽喉炎患者的效果.方法:选择在2011-07/2014-07湖北医药学院附属人民医院收治的130例食管反流性咽喉炎患者,将患者随机分为给予莫沙必利联合雷尼替丁治疗的对照组,和给予莫沙必利与雷贝拉唑联合治疗的治疗组,每组65例,然后将对照组患者与治疗组患者的治疗总有效率、食管的p H值<4时间百分比和临床症状总分等指标进行比较.结果:在治疗组患者中,治疗的总有效率为95.38%,给予常规治疗的对照组患者中,治疗的总有效率为67.69%.治疗组优于对照组,组间差异有统计学意义(P<0.05);在治疗后,两组患者的第一通道p H<4时间百分比、第二通道p H<4时间百分比以及临床症状总分均较治疗前有改善,同时,治疗组改善效果明显优于对照组,差异均有统计学意义(P<0.05);两组患者在不良反应发生率上差异无统计学意义(P>0.05).结论:应用莫沙必利与雷贝拉唑联合治疗食管反流性咽喉炎,具有显著的治疗效果、减轻临床症状并且安全性高,有着重要的临床参考意义.

AIM： To investigate the clinical effects of mosapride plus rabeprazole in patients with esophageal reflux laryngitis. METHODS： One hundred and thirty esophageal reflux laryngitis patients treated at the Affiliated People＇s Hospital of Hubei Medical College from July 2011 to July 2014 were randomly divided into either a control group to receive mosapride plus ranitidine or a study group to receive mosapride and rabeprazole, with 65 cases in each group, The total response rate, percentage of time with pH 〈 4, and clinical symptom score were compared for the two groups. RESULTS： The total response rate was significantly higher in the study group than in the control group （95.38% vs 67.69%, P 〈 0.05）. After treatment, percentage of time with pH 〈 4 and clinical symptom score were significantly improved in both groups compared with pretreatment values, and the improvement was more significant in the study group than in the control group （P 〈 0.05）. There was no significant difference between the two groups in the incidence of adverse reactions （P 〉 0.05）. CONCLUSION： Mosapride plus rabeprazole has a significant therapeutic effect in treating esophageal reflux laryngitis, and the combination therapy can reduce symptoms and has high safety.